-
Questions Remain for Zafgen (ZFGN) Following Today's Beloranib Update - RBC
-
RBC Capital Sees Attractive Risk/Reward in Zafgen (ZFGN)
-
Zafgen (ZFGN) PT Lowered to $46 at RBC Capital; Discusses Road Ahead for Beloranib
-
RBC Sees 33% of Zafgen (ZFGN) Death Happening in Placebo Arm; Reiterates 'Outperform' Rating
-
Zafgen (ZFGN) Worst Case Scenario Avoided, RBC Capital - Bloomberg
-
Zafgen (ZFGN) Won't Comment on 56% Stock Plunge
-
Zafgen (ZFGN) Continues Free Fall Into Close Amid Radio Silence
-
Streetinsider.com's Hot Lunchtime Reads 10/13: (TSLA) (TXMD) (FIG) (ACI)
-
RBC Capital Discusses Theoretical Scenarios Following Zafgen's (ZFGN) Plunge
-
Zafgen (ZFGN) PT Lifted to $58 at RBC Capital Despit bestPWS Phase III Being Pushed Out a Bit
-
RBC Capital Starts Zafgen (ZFGN) at Outperform

